EZH2 inactivation cooperates with HOXA9 to induce leukemic transformation of human t-cell progenitors and sustain high-risk subsets of early t-cell precursor acute lymphoblastic leukemia (ETP-ALL) Free

Early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL) is an aggressive hematological malignancy characterized by the uncontrolled expansion of T-cell progenitors. Loss-of-function mutations in genes encoding epigenetic regulators, including core components of the Polycomb Repressive Complex 2 (PRC2), such as the EZH2 histone methyltransferase, are frequently observed in ETP-ALL patients.To investigate the role of EZH2 inactivation in human early T-cell leukemogenesis, we optimized a CRISPR/Cas9-based strategy to disrupt EZH2 gene expression by integrating a DNA cassette containing the constitutive human PGK-1 promoter followed by the GFP reporter. Specifically, human CD34⁺ hematopoietic stem/progenitor cells (HSPCs) derived from cord blood were first edited to knock out (KO) EZH2, then transduced with lentiviruses encoding different T-ALL oncogenes or an empty vector control, and maintained in serum-free medium supplemented to support T-cell progenitor expansion. We found that only HOXA9- and LYL1-transduced EZH2^KO HSPCs expanded in vitro for up to 30 days, and were enriched for early T-cell subsets, as identified by single-cell RNA sequencing (scRNA-seq) and a 26-color flow cytometry assay. Notably, these same subsets were capable of initiating T-cell leukemia in immunocompromised (NSG) mice following transplantation, suggesting that EZH2 inactivation cooperates with HOXA9 or LYL1 overexpression to drive human T-cell transformation. To assess the relevance of these findings in primary human T-ALLs, we analyzed whether loss-of-function mutations in PRC2 genes (EZH2, EED, SUZ12) were enriched in specific T-ALL subgroups, particularly ETP-ALL, in a cohort of 1,335 patients from the Children's Oncology Group (COG) study. Interestingly, PRC2-mutated T-ALLs were significantly associated with the HOXA subgroup and the ETP-ALL phenotype, and exhibited higher levels of minimal residual disease (MRD) 30 days after therapy compared to other T-ALL cases. To further dissect the molecular effects of EZH2 loss and HOXA9 overexpression in ETP-like T-ALL, we knocked out EZH2 in the human Loucy and PEER cell lines using CRISPR/Cas9. These EZH2^KOcells were then transduced with HOXA9-encoding lentiviruses or empty vectors and analyzed by RNA sequencing. In parallel, ChIP-seq analyses were performed to map HOXA9 binding sites and assess histone modifications affected by EZH2 loss. Integrated analysis of RNA-seq and ChIP-seq data revealed that HOXA9 expression in EZH2-deficient ETP-like cells led to the upregulation of a stem-like/immature T-cell gene signature enriched in transcriptional activators and chromatin remodelers (e.g., RUNX2, IRX3, SATB1, ARID5B, CHD1, INO80D).Furthermore, scRNA-seq profiling of primary PRC2-mutated T-ALL samples revealed distinct leukemic subsets with high HOXA9 expression and strong enrichment for the same gene signature, as determined by Gene Set Variation Analysis (GSVA). Importantly, this signature stratified PRC2-mutated T-ALLs and identified a HOXA positive subgroup associated with poor prognosis.

Collectively, these findings uncover a critical epigenetic circuit involving EZH2 loss and HOXA9-driven transcriptional reprogramming that promotes stem-like, therapy-resistant T-ALL subsets and highlights novel vulnerabilities that could be therapeutically exploited to eliminate high-risk disease at its origin.